Clinical Evidence

MolecuLight i:X in the Chronic Wound Treatment Pathway

Incorporating the MolecuLight i:X into standard care helps clinicians detect fluorescent bacteria 2,9,11 and facilitates evidence-based clinician decision making which may support every stage of wound care:

Patient Education and Engagement

Patients easily see and understand why a clinican is taking certain action to clean, debride and treat a wound in a specific way.4,5

Documentation

Provides objective visual documentation of the presence of fluorescent bacteria and the surface area of the wound.2,9

Antibiotic Decision Making

Supports more responsible antibiotic decision making and selection.6,8,9

Treatment Choice

Comparing fluorescent bacteria and wound surface area at each visit may provide real-time objective feedback on impact of treatment plan.1,2,4

Device-Front-reflect-and-shadow

Wound Assessment

Visualise fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.1,3

Cleaning

Allows clinicians to focus cleaning in areas where fluorescent bacteria are located and optimize wound bed preparation.10

Sampling

Guides where to sample 54% more accurate swabbing compared to the Levine Technique.3

Debridement

Guides more efficient and targeted debridement.2,6,7

Pseudomonas aeruginosa fluoresces cyan if present.

1. Wu, YC. et al. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. Int Wound J. 2016 Aug;13(4):449-53.
2. DaCosta, R. S. et al. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).
3. Ottolino-Perry, K. et al. Improved detection of wound bacteria using fluorescence image-guided wound sampling in diabetic foot ulcers. Int Wound J. 2017 Feb 28.
4. Raizman, R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at: CAWC 2016. Proceedings of the 22nd Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON.
5. Raizman, R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.
6. Landis, S. J. Mapping venous ulcers using bacterial autofluorescence (BAF) to identify subgroups at risk of infection post debridement. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON.
7. Hoeflok, J. et al. Pilot clinical evaluation of surgical site infections with a novel handheld fluorescence imaging device. Proceedings of the Annual Military Health System Research Symposium (MHSRS); 2014 Aug 18-21; Fort Lauderdale, FL.
8. Hill, R. et al. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Proceedings of the Annual Symposium on Advanced Wound Care (SAWC); 2017 Apr 5-9; San Diego, CA. (accepted).
9. MolecuLight® Inc. Case Study 0051 Track Wound Size and Bacterial Presence with the MolecuLight i:X 2016.
10. Raizman, R. (2016) Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Proceedings of the Innovations in Wound Healing Conference; Dec 8-11, Key Largo, FL.
11. MolecuLight® Inc. PN 1189 MolecuLight i:X User Manual. 2016.